Recent developments regarding periostin in bronchial asthma

Allergology International

Volumn 64, Issue , 2015, Pages S3-S10

  Izuhara, Kenji ^a   Matsumoto, Hisako ^b   Ohta, Shoichiro ^a   Ono, Junya ^c   Arima, Kazuhiko ^a   Ogawa, Masahiro ^a  

^a SAGA UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c SHINO TEST CORPORATION   (Japan)

Author keywords

Biomarker; Bronchial asthma; Companion diagnostic; Periostin; Stratified medicine

Indexed keywords

CORTICOSTEROID; INTERLEUKIN 13; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 5 ANTIBODY; TRANSCRIPTION FACTOR RUNX2; ANTIASTHMATIC AGENT; AUTACOID; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; POSTN PROTEIN, HUMAN;

AIRWAY REMODELING; ALLERGIC AIRWAY INFLAMMATION; ARTICLE; ASTHMA; BLOOD LEVEL; DRUG RESPONSE; FIBROSIS; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BLOOD; DRUG DEVELOPMENT; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; PROGNOSIS; TREATMENT OUTCOME;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BIOMARKERS; CELL ADHESION MOLECULES; DRUG DISCOVERY; HUMANS; INFLAMMATION MEDIATORS; MOLECULAR TARGETED THERAPY; PROGNOSIS; TREATMENT OUTCOME;

EID: 84941025322     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.1016/j.alit.2015.04.012     Document Type: Review

References (56)

1. S.E. Wenzel Asthma phenotypes: the evolution from clinical to molecular approaches Nat Med 18 2012 716 725
2. Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention 2014 Available from: www.ginasthma.org
3. I.M. Adcock, and S.J. Lane Corticosteroid-insensitive asthma: molecular mechanisms J Endocrinol 178 2003 347 355
4. R.L. Sorkness, E.R. Bleecker, W.W. Busse, W.J. Calhoun, M. Castro, K.F. Chung, and et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation J Appl Physiol 104 2008 394 403
5. J. Bousquet, K. Rabe, M. Humbert, K.F. Chung, W. Berger, H. Fox, and et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma Respir Med 101 2007 1483 1492
6. H. Matsumoto Serum periostin: a novel biomarker for asthma management Allergol Int 63 2014 153 160
7. K. Izuhara, K. Arima, S. Ohta, S. Suzuki, M. Inamitsu, and K. Yamamoto Periostin in allergic inflammation Allergol Int 63 2014 143 151
8. K. Takatsu Interleukin-5 and IL-5 receptor in health and diseases Proc Jpn Acad Ser B Phys Biol Sci 87 2011 463 485
9. A.N. McKenzie, H. Spits, and G. Eberl Innate lymphoid cells in inflammation and immunity Immunity 41 2014 366 374
10. P.S. Foster, S.P. Hogan, A.J. Ramsay, K.I. Matthaei, and I.G. Young Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model J Exp Med 183 1996 195 201
11. M.J. Leckie, A. ten Brinke, J. Khan, Z. Diamant, B.J. O'Connor, C.M. Walls, and et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response Lancet 356 2000 2144 2148
12. J.C. Kips, B.J. O'Connor, S.J. Langley, A. Woodcock, H.A. Kerstjens, D.S. Postma, and et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study Am J Respir Crit Care Med 167 2003 1655 1659
13. P. Haldar, C.E. Brightling, B. Hargadon, S. Gupta, W. Monteiro, A. Sousa, and et al. Mepolizumab and exacerbations of refractory eosinophilic asthma N Engl J Med 360 2009 973 984
14. P. Nair, M.M. Pizzichini, M. Kjarsgaard, M.D. Inman, A. Efthimiadis, E. Pizzichini, and et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia N Engl J Med 360 2009 985 993
15. H.G. Ortega, M.C. Liu, I.D. Pavord, G.G. Brusselle, J.M. FitzGerald, A. Chetta, and et al. Mepolizumab treatment in patients with severe eosinophilic asthma N Engl J Med 371 2014 1198 1207
16. E.H. Bel, S.E. Wenzel, P.J. Thompson, C.M. Prazma, O.N. Keene, S.W. Yancey, and et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma N Engl J Med 371 2014 1189 1197
17. D.B. Corry, H.G. Folkesson, M.L. Warnock, D.J. Erle, M.A. Matthay, J.P. Wiener-Kronish, and et al. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity J Exp Med 183 1996 109 117
18. M. Wills-Karp, J. Luyimbazi, X. Xu, B. Schofield, T.Y. Neben, C.L. Karp, and et al. Interleukin-13: central mediator of allergic asthma Science 282 1998 2258 2261
19. G. Grünig, M. Warnock, A.E. Wakil, R. Venkayya, F. Brombacher, D.M. Rennick, and et al. Requirement for IL-13 independently of IL-4 in experimental asthma Science 282 1998 2261 2263
20. K. Izuhara, K. Arima, S. Kanaji, S. Ohta, and T. Kanaji IL-13: a promising therapeutic target for bronchial asthma Curr Med Chem 13 2006 2291 2298
21. J. Corren, R.F. Lemanske, N.A. Hanania, P.E. Korenblat, M.V. Parsey, J.R. Arron, and et al. Lebrikizumab treatment in adults with asthma N Engl J Med 365 2011 1088 1098
22. E. Piper, C. Brightling, R. Niven, C. Oh, R. Faggioni, K. Poon, and et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma Eur Respir J 41 2013 330 338
23. L.A. Beck, D. Thaci, J.D. Hamilton, N.M. Graham, T. Bieber, R. Rocklin, and et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis N Engl J Med 371 2014 130 139
24. S. Wenzel, D. Wilbraham, R. Fuller, E.B. Getz, and M. Longphre Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies Lancet 370 2007 1422 1431
25. J. Corren, W. Busse, E.O. Meltzer, L. Mansfield, G. Bensch, J. Fahrenholz, and et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Rα antagonist, in patients with asthma Am J Respir Crit Care Med 181 2010 788 796
26. G.M. Gauvreau, L.P. Boulet, D.W. Cockcroft, J.M. Fitzgerald, C. Carlsten, B.E. Davis, and et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma Am J Respir Crit Care Med 183 2011 1007 1014
27. N.A. Hanania, S. Wenzel, K. Rosen, H.J. Hsieh, S. Mosesova, D.F. Choy, and et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study Am J Respir Crit Care Med 187 2013 804 811
28. Z. Zhu, R.J. Homer, Z. Wang, Q. Chen, G.P. Geba, J. Wang, and et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production J Clin Invest 103 1999 779 788
29. D.A. Kuperman, X. Huang, L.L. Koth, G.H. Chang, G.M. Dolganov, Z. Zhu, and et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma Nat Med 8 2002 885 889
30. N. Yuyama, D.E. Davies, M. Akaiwa, K. Matsui, Y. Hamasaki, Y. Suminami, and et al. Analysis of novel disease-related genes in bronchial asthma Cytokine 19 2002 287 296
31. G. Takayama, K. Arima, T. Kanaji, S. Toda, H. Tanaka, S. Shoji, and et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals J Allergy Clin Immunol 118 2006 98 104
32. N. Hayashi, T. Yoshimoto, K. Izuhara, K. Matsui, T. Tanaka, and K. Nakanishi T helper 1 cells stimulated with ovalbumin and IL-18 induce airway hyperresponsiveness and lung fibrosis by IFN-γ and IL-13 production Proc Natl Acad Sci U S A 104 2007 14765 14770
33. P.G. Woodruff, H.A. Boushey, G.M. Dolganov, C.S. Barker, Y.H. Yang, S. Donnelly, and et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids Proc Natl Acad Sci U S A 104 2007 15858 15863
34. P.G. Woodruff, B. Modrek, D.F. Choy, G. Jia, A.R. Abbas, A. Ellwanger, and et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma Am J Respir Crit Care Med 180 2009 388 395
35. M.C. Peters, Z.K. Mekonnen, S. Yuan, N.R. Bhakta, P.G. Woodruff, and J.V. Fahy Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma J Allergy Clin Immunol 133 2014 388 394
36. S. Sehra, W. Yao, E.T. Nguyen, A.N. Ahyi, F.M. Tuana, S.K. Ahlfeld, and et al. Periostin regulates goblet cell metaplasia in a model of allergic airway inflammation J Immunol 186 2011 4959 4966
37. E.D. Gordon, S.S. Sidhu, Z.E. Wang, P.G. Woodruff, S. Yuan, M.C. Solon, and et al. A protective role for periostin and TGF-β in IgE-mediated allergy and airway hyperresponsiveness Clin Exp Allergy 42 2012 144 155
38. J.K. Bentley, Q. Chen, J.Y. Hong, A.P. Popova, J. Lei, B.B. Moore, and et al. Periostin is required for maximal airways inflammation and hyperresponsiveness in mice J Allergy Clin Immunol 134 2014 1433 1442
39. Y. Kanemitsu, I. Ito, A. Niimi, K. Izuhara, S. Ohta, J. Ono, and et al. Osteopontin and periostin are associated with a 20-year decline of pulmonary function in patients with asthma Am J Respir Crit Care Med 190 2014 472 474
40. S.S. Sidhu, S. Yuan, A.L. Innes, S. Kerr, P.G. Woodruff, L. Hou, and et al. Roles of epithelial cell-derived periostin in TGF-β activation, collagen production, and collagen gel elasticity in asthma Proc Natl Acad Sci U S A 107 2010 14170 14175
41. T. Shoda, K. Futamura, F. Kobayashi, H. Saito, K. Matsumoto, and A. Matsuda Cell type-dependent effects of corticosteroid on periostin production by primary human tissue cells Allergy 68 2013 1467 1470
42. Y. Nakamura, H. Nagashima, S. Ohta, J. Ono, K. Yamauchi, and K. Izuhara Periostin in the bronchial lavage fluid of asthma patients Allergol Int 64 2015 209 210
43. M. Matsusaka, H. Kabata, K. Fukunaga, Y. Suzuki, K. Masaki, T. Mochimaru, and et al. Phenotype of asthma related with high serum periostin levels Allergol Int 64 2015 175 180
44. Y. Kanemitsu, H. Matsumoto, K. Izuhara, Y. Tohda, H. Kita, T. Horiguchi, and et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids J Allergy Clin Immunol 132 2013 305 312
45. M.A. Kim, K. Izuhara, S. Ohta, J. Ono, M.K. Yoon, G.Y. Ban, and et al. Association of serum periostin with aspirin-exacerbated respiratory disease Ann Allergy Asthma Immunol 113 2014 314 320
46. G. Jia, R.W. Erickson, D.F. Choy, S. Mosesova, L.C. Wu, O.D. Solberg, and et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients J Allergy Clin Immunol 130 2012 647 654
47. NO and serum periostin as surrogates for sputum eosinophils in asthma Thorax 70 2015 115 120
48. J.R. Arron, and K. Izuhara Asthma biomarkers: what constitutes a 'gold standard'? Thorax 70 2015 105 107
49. J.H. Choi, M.A. Kim, and H.S. Park An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease Curr Opin Allergy Clin Immunol 14 2014 1 6
50. T. Nagasaki, H. Matsumoto, Y. Kanemitsu, K. Izuhara, Y. Tohda, T. Horiguchi, and et al. Using exhaled nitric oxide and serum periostin as a composite marker to identify severe/steroid-insensitive asthma Am J Respir Crit Care Med 190 2014 1449 1452
51. M.A. Kim, Y.S. Shin, D. Pham le, and H.S. Park Adult asthma biomarkers Curr Opin Allergy Clin Immunol 14 2014 49 54
52. J.F. Donohue, and N. Jain Exhaled nitric oxide to predict corticosteroid responsiveness and reduce asthma exacerbation rates Respir Med 107 2013 943 952
53. K.F. Chung, P. Godard, E. Adelroth, J. Ayres, N. Barnes, P. Barnes, and et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS task force on Difficult/Therapy-Resistant Asthma. European respiratory Society Eur Respir J 13 1999 1198 1208
54. S. Wenzel Severe asthma in adults Am J Respir Crit Care Med 172 2005 149 160
55. T. Nagasaki, H. Matsumoto, Y. Kanemitsu, K. Izuhara, Y. Tohda, H. Kita, and et al. Integrating longitudinal informetionon pulmonary function and inflammation using asthma phenotypes J Allergy Clin Immunol 133 2014 1474 1477
56. G. Kato, K. Takahashi, K. Izuhara, K. Komiya, S. Kimura, and S. Hayashi Markers that can reflect asthmatic activity before and after reduction of inhaled corticosteroids: a pilot study Biomark Insights 8 2013 97 105